NasdaqCM - Delayed Quote • USD
MEI Pharma, Inc. (MEIP)
At close: 4:00 PM EDT
Breakdown
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Total Revenue
72,648.0000
48,816.0000
40,697.0000
34,796.0000
27,756.0000
Cost of Revenue
--
--
--
1,408.0000
2,671.0000
Gross Profit
--
--
40,697.0000
33,388.0000
25,085.0000
Operating Expense
56,768.0000
85,580.0000
116,181.0000
93,812.0000
50,782.0000
Operating Income
15,880.0000
-36,764.0000
-75,484.0000
-60,424.0000
-25,697.0000
Net Non Operating Interest Income Expense
3,983.0000
3,345.0000
284.0000
510.0000
1,395.0000
Other Income Expense
-19.0000
1,581.0000
20,746.0000
18,608.0000
-22,870.0000
Pretax Income
19,844.0000
-31,838.0000
-54,454.0000
-41,306.0000
-47,172.0000
Tax Provision
--
--
--
8.0000
1.0000
Net Income Common Stockholders
19,844.0000
-31,838.0000
-54,454.0000
-41,314.0000
-47,173.0000
Average Dilution Earnings
-14,357.0000
--
-8,046.0000
-27,394.0000
--
Diluted NI Available to Com Stockholders
19,844.0000
-31,838.0000
-62,500.0000
-68,708.0000
-47,173.0000
Basic EPS
2.98
-4.78
-8.75
-7.40
-10.40
Diluted EPS
2.98
-4.78
-9.99
-12.00
-10.40
Basic Average Shares
6,663.0000
6,663.0000
6,224.0000
5,626.3500
4,554.0000
Diluted Average Shares
6,663.0000
6,663.0000
6,257.0000
5,724.0500
4,554.0000
Total Operating Income as Reported
15,880.0000
-36,764.0000
-75,484.0000
-60,424.0000
-25,697.0000
Total Expenses
56,768.0000
85,580.0000
116,181.0000
95,220.0000
53,453.0000
Net Income from Continuing & Discontinued Operation
19,844.0000
-31,838.0000
-54,454.0000
-41,314.0000
-47,173.0000
Normalized Income
19,844.0000
-33,441.0000
-75,206.0000
-59,436.0000
-24,303.0000
Interest Income
3,983.0000
3,345.0000
284.0000
510.0000
1,395.0000
Net Interest Income
3,983.0000
3,345.0000
284.0000
510.0000
1,395.0000
EBIT
15,880.0000
-36,764.0000
-75,484.0000
-60,424.0000
-25,697.0000
EBITDA
16,247.0000
-36,378.0000
-75,158.0000
-60,139.0000
-25,588.0000
Reconciled Cost of Revenue
--
--
--
1,408.0000
2,671.0000
Reconciled Depreciation
367.0000
386.0000
326.0000
285.0000
109.0000
Net Income from Continuing Operation Net Minority Interest
19,844.0000
-31,838.0000
-54,454.0000
-41,314.0000
-47,173.0000
Total Unusual Items Excluding Goodwill
--
1,603.0000
20,752.0000
18,122.0000
-22,870.0000
Total Unusual Items
--
1,603.0000
20,752.0000
18,122.0000
-22,870.0000
Normalized EBITDA
16,247.0000
-37,981.0000
-95,910.0000
-78,261.0000
-2,718.0000
Tax Rate for Calcs
0.0002
--
--
--
--
6/30/2020 - 12/18/2003
Yahoo Finance Plus Essential access required. Unlock Access
Related Tickers
REVB Revelation Biosciences, Inc.
2.2400
+1.36%
PRTC PureTech Health plc
26.15
-0.46%
DSGN Design Therapeutics, Inc.
3.7000
-1.07%
BOLT Bolt Biotherapeutics, Inc.
1.1100
-2.63%
AKTX Akari Therapeutics, Plc
1.1662
-0.32%
GNTA Genenta Science S.p.A.
3.9010
-0.74%
CYCN Cyclerion Therapeutics, Inc.
3.5000
+5.58%
LXEO Lexeo Therapeutics, Inc.
12.05
-0.17%
GRI GRI Bio, Inc.
0.5279
+2.43%
ANTX AN2 Therapeutics, Inc.
2.4700
+3.78%